

NIH AIDS Reagent Program

20301 Century Boulevard Building 6, Suite 200 Germantown, MD 20874 USA

Phone: 240 686 4740 Fax: 301 515 4015 aidsreagent.org

DATA SHEET

Reagent:	J-Lat Full Length Cells (9.2)
Catalog Number:	9848
Lot Number:	040602
Release Category:	C
Provided:	1 x 10 ⁷ cells/vial.
Cell Type:	Jurkat - T lymphocyte cell line
Propagation Medium:	RPMI 1640, 90%; FBS, 10%; supplemented with penicillin G (100 U/ml), streptomycin (100 µg/ml), L-glutamine (2 mM, 0.3 mg/ml).
Freeze Medium:	FBS, 90%; DMSO, 10%.
Growth Characteristics:	No special requirements, split 1:3 at 1×10^7 cells/ml. Cells grow in suspension, usually singly but some clumping has been noted.
Morphology:	Small, spherical cells in suspension. Morphology usually does not vary.
Sterility:	Negative for bacteria, mycoplasma, and fungi.
Description:	This is a Jurkat-based cell line containing a full-length integrated HIV-1 genome that expresses GFP upon activation. The genome generates incomplete virions due to a frameshift in env.
Special Characteristics:	Jurkat cells were infected with the packaged retroviral construct HIV-R7/E-/GFP, which is full length HIV-1 genome with a non-functional Env due to a frameshift, and GFP in place of the Nef gene.
	Full-length constructs secrete incomplete viral particles (capsids). The cells express low to undetectable levels of GFP under basal conditions. Suited to study HIV latency and reactivation.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

	The clones in this series are: 6.3 (cat# 9846), 8.4 (cat# 9847), 9.2 (cat# 9848), 10.6 (cat# 9849), and 15.4 (cat# 9850).
	Please see Table I in the reference publication for differences between these clones in GFP and p24 expression upon stimulation with TNF-a $$
Recommended Storage:	Liquid nitrogen.
Contributor:	Dr. Eric Verdin.
References:	Jordan, A., Bisgrove, D., & Verdin, E. (2003). HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J, 22(8), 1868-1877. doi:10.1093/emboj/cdg188 PUBMED
NOTE:	Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: J-Lat Full Length GFP Cells (clone #) from Dr. Eric Verdin." Also include the reference cited above in any publication.
	These cells and methods of use are covered by US Patents 7,232,685 and 7,544,467.
	Scientists at for-profit institutions or who intend commercial use of this reagent must contact the J. David Gladstone Institutes, Email: <u>veronica.viray@gladstone.ucsf.edu</u> , before the reagent can be released. Please specify the name and a description of the intended use of the reagent.
Last Updated	November 09, 2017

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.